Study conduct in groups [Design Issues]

posted by ElMaestro  – Denmark, 2015-02-02 09:21 (4166 d 16:47 ago) – Posting: # 14347
Views: 29,847

Hi Smitha,

❝ If a Bioequivalence study has to be conducted in 2 groups (say 20 volunteers each), does the FDA or EMA require that all 40 volunteers be recruited into the study before Group 1 Period 1 dosing? :confused:


That's an interesting question. At least, I never gave it any thought, but of course that doesn't mean much.
If I get you right you are asking if you you need 40 signed ICF's before dosing your first subject. No guideline discusses it, I think.

I can't offer an answer, but I think I would play it safe. In a trial with 20 subject and 2 backups you would ordinarily have all 22 ICF's signed before the first subject is dosed. If the backups are needed the trial is in a sense having two groups, right? Only the second group is rather small, but in a sense it serves the same purposes: getting the desired number of subjects.
Also if you start a study when 20 ICFs are available and you cannot execute group 2 because you for some reason are running out of eligibles then all manners of GCP hell could ensue. Thus, I am leaning towards treating 20+20 like 20+2.

This is just one opinion and not a very qualified one. I hope others will chime in as I believe there might also be arguments for doing it the other way. So I will go make some popcorn and will watch this thread with interest.

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,571 registered users;
257 visitors (0 registered, 257 guests [including 37 identified bots]).
Forum time: 03:09 CEST (Europe/Vienna)

Try to learn something about everything
and everything about something.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5